Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 25;10(10):e005635. doi: 10.1136/jitc-2022-005635

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Characteristic histological findings from patients with liver-related irAE. (A) Patient 8. ICI-related hepatitis. Prominent inflammation is seen in the portal tract (PT) with interface hepatitis (arrows), together with multiple foci of inflammation and apoptotic bodies in the lobule (*). Scale bar, 200 µm. (B) Patient 20. ICI-related cholangitis. A florid inflammatory duct lesion is found in a large PT (arrow) with no inflammation or apoptosis within the lobule. Scale bar, 200 µm. (C) Patient 22. ICI-related cholangiohepatitis. Both portal inflammation with interface hepatitis (arrow) and an irregular bile duct with ductular reaction (arrowheads) are observed. Scale bar, 200 µm. ICI, immune checkpoint inhibitor; irAE, immune-related adverse events.